[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 36 of about 36
1. Li MH, Huang KL, Wu SY, Chen CW, Yan HC, Hsu K, Hsu CW, Tsai SH, Chu SJ: Baicalin attenuates air embolism-induced acute lung injury in rat isolated lungs. Br J Pharmacol; 2009 May;157(2):244-51
Hazardous Substances Data Bank. MALONALDEHYDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Baicalin attenuates air embolism-induced acute lung injury in rat isolated lungs.
  • BACKGROUND AND PURPOSE: Baicalin has been reported to have anti-inflammatory effects and protect against various tissue injuries.
  • However, the effect of baicalin on air embolism-induced acute lung injury has not been tested yet.
  • EXPERIMENTAL APPROACH: Acute lung injury was induced by infusion of air at a rate of 0.25 mL.min(-1) for 1 min into the pulmonary artery of rat isolated lungs.
  • KEY RESULTS: Air embolism elicited a significant increase in microvascular permeability (K(f)), lung weight gain, wet/dry weight ratio, pulmonary artery pressure and protein concentration in the bronchoalveolar lavage fluid.
  • Levels of the cytokines, tumour necrosis factor alpha and cytokine-induced neutrophil chemoattractant-1 in perfusate, and malondialdehyde levels and myeloperoxidase activities in lung tissue were also significantly increased.
  • In addition, histological examination showed increased neutrophil infiltration in lung tissues.
  • Pretreatment of the lungs with baicalin (4 mg.kg(-1)) showed a statistically significant difference in all of the assessed parameters, except for alteration in the pulmonary artery pressure.
  • CONCLUSIONS AND IMPLICATIONS: Our study suggests that baicalin attenuated air embolism-induced acute lung injury and may be considered a useful adjunct drug therapy in this clinical condition.
  • [MeSH-major] Embolism, Air / prevention & control. Flavonoids / therapeutic use. Lung Injury / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Feb 17;342(7):476-82 [10675429.001]
  • [Cites] Br J Pharmacol. 2008 Mar;153 Suppl 2:S1-209 [18347570.001]
  • [Cites] Cytokine Growth Factor Rev. 2003 Dec;14(6):523-35 [14563354.001]
  • [Cites] Anesth Analg. 2003 Dec;97(6):1724-9 [14633550.001]
  • [Cites] Circ Res. 1981 Mar;48(3):344-51 [7460207.001]
  • [Cites] Chem Pharm Bull (Tokyo). 1984 Jul;32(7):2724-9 [6499085.001]
  • [Cites] J Appl Physiol (1985). 1988 Mar;64(3):929-35 [3366749.001]
  • [Cites] J Appl Physiol (1985). 1992 Apr;72(4):1235-42 [1592709.001]
  • [Cites] Am J Physiol. 1995 Feb;268(2 Pt 1):L245-50 [7532369.001]
  • [Cites] J Immunol. 1997 Jul 1;159(1):391-400 [9200478.001]
  • [Cites] N Engl J Med. 1998 Feb 12;338(7):436-45 [9459648.001]
  • [Cites] Arch Toxicol. 2005 Feb;79(2):102-9 [15645217.001]
  • [Cites] Chest. 2005 Jul;128(1):327-36 [16002954.001]
  • [Cites] Crit Care Med. 2005 Sep;33(9):2056-60 [16148480.001]
  • [Cites] J Ethnopharmacol. 2005 Oct 3;101(1-3):68-74 [15878812.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2006 Apr;290(4):L622-L645 [16531564.001]
  • [Cites] Immunobiology. 2006;211(5):359-68 [16716805.001]
  • [Cites] Mech Ageing Dev. 2006 Sep;127(9):719-25 [16766019.001]
  • [Cites] Brain Res. 2006 Dec 6;1123(1):188-95 [17069775.001]
  • [Cites] Neuropharmacology. 2007 Mar;52(3):1024-33 [17204294.001]
  • [Cites] Chest. 2007 Mar;131(3):913-20 [17356114.001]
  • [Cites] Mediators Inflamm. 2006;2006(5):26295 [17392571.001]
  • [Cites] Liver Int. 2007 May;27(4):582-91 [17403198.001]
  • [Cites] Eur J Pharmacol. 2007 Jul 2;566(1-3):58-66 [17475241.001]
  • [Cites] J Ethnopharmacol. 2007 Jul 25;112(3):537-44 [17537603.001]
  • [Cites] Dig Dis Sci. 2008 Feb;53(2):581-91 [17549629.001]
  • [Cites] J Clin Monit Comput. 2000;16(5-6):375-83 [12580220.001]
  • (PMID = 19309358.001).
  • [ISSN] 1476-5381
  • [Journal-full-title] British journal of pharmacology
  • [ISO-abbreviation] Br. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Flavonoids; 0 / NF-kappa B; 347Q89U4M5 / baicalin; 4Y8F71G49Q / Malondialdehyde
  • [Other-IDs] NLM/ PMC2697809
  •  go-up   go-down


2. Schrama JG, Holtkamp MJ, Baars JW, Schornagel JH, Rodenhuis S: Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience. Br J Cancer; 2003 Jun 16;88(12):1831-8
Hazardous Substances Data Bank. THIO-TEPA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience.
  • High-dose chemotherapy (HD-CT) has a role in the potentially curative treatment of several tumours.
  • Most patients had high-risk (n=86) or metastatic (n=4) breast cancer, or a germ cell tumour (n=8).
  • Most patients had PBPC-Tx with granulocyte colony-stimulating factor (G-CSF), and the median time to neutrophil count 500 x 10(6) l(-1) and platelet count >20 x 10(9) l(-1) without transfusion independence was 10 (range 8-25) and 13 (8-60) days, respectively.
  • Reversible cardiac toxicity was seen in six patients and pulmonary events occurred in seven patients (infection (n=6), embolism (n=1)).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / toxicity. Breast Neoplasms / drug therapy. Carboplatin / toxicity. Cyclophosphamide / toxicity. Germinoma / drug therapy. Thiotepa / toxicity
  • [MeSH-minor] Adult. Bone Marrow / drug effects. Drug Administration Schedule. Follow-Up Studies. Hemorrhage / complications. Humans. Infection / complications. Male. Middle Aged. Netherlands

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1996 May;14(5):1473-83 [8622061.001]
  • [Cites] Cancer Chemother Pharmacol. 1996;37(6):561-8 [8612310.001]
  • [Cites] J Natl Cancer Inst. 1998 Feb 4;90(3):210-8 [9462678.001]
  • [Cites] Lancet. 1998 Aug 15;352(9127):515-21 [9716055.001]
  • [Cites] Clin Cancer Res. 1996 Sep;2(9):1481-7 [9816324.001]
  • [Cites] Ann Oncol. 1999 May;10(5):511-7 [10415999.001]
  • [Cites] Ann Oncol. 1999 Dec;10(12):1467-73 [10643538.001]
  • [Cites] N Engl J Med. 2000 Apr 13;342(15):1069-76 [10760307.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;46(2):119-27 [10972481.001]
  • [Cites] Oncologist. 2000;5(5):369-75 [11040272.001]
  • [Cites] J Neurooncol. 2001 Jan;51(2):159-65 [11386413.001]
  • [Cites] Bone Marrow Transplant. 2001 Jul;28(2):173-80 [11509935.001]
  • [Cites] Lancet. 2000 Oct 21;356(9239):1384-91 [11052580.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):58-64 [11773154.001]
  • [Cites] Ther Drug Monit. 2001 Dec;23(6):650-7 [11802099.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Ann Oncol. 2002 Mar;13(3):374-84 [11996467.001]
  • [Cites] Ann Oncol. 2002 May;13(5):689-98 [12075736.001]
  • [Cites] Semin Oncol. 1990 Feb;17(1 Suppl 3):18-32 [2106164.001]
  • [Cites] Semin Oncol. 1990 Feb;17(1 Suppl 3):2-6 [2106165.001]
  • [Cites] J Clin Oncol. 1992 Jan;10(1):102-10 [1727912.001]
  • [Cites] Ann Oncol. 1992 Dec;3(10):855-60 [1286049.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1132-43 [8501500.001]
  • [Cites] Br J Cancer. 1995 Apr;71(4):857-62 [7536025.001]
  • [Cites] Cancer Chemother Pharmacol. 1995;37(1-2):155-60 [7497586.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1870-9 [9164197.001]
  • (PMID = 12799623.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; 905Z5W3GKH / Thiotepa; BG3F62OND5 / Carboplatin; CTCb regimen
  • [Other-IDs] NLM/ PMC2741114
  •  go-up   go-down


3. Batra R, Davies JN, Wheatley D: Extensive arterial and venous thrombo-embolism with chemotherapy for testicular cancer: a case report. Cases J; 2009;2:9082

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive arterial and venous thrombo-embolism with chemotherapy for testicular cancer: a case report.
  • Germ cell tumours tend to affect young adults and with advanced treatments achieve more than 90% cure rates.
  • Over the years cisplatin has significantly improved the relapse free survival in these patients, hence forming an essential component of chemotherapy regimes.
  • But, the thrombo-embolic complications suffered with cisplatin significantly affect the quality of life in these young patients.We describe a young adult who suffered a potentially fatal cerebral and pulmonary vascular insult on completing first cycle of cisplatin-based chemotherapy for a non-seminomatous germ cell tumour.
  • Venous and arterial thrombo-embolism was the mechanism of injury and was promptly managed surgically and medically including neuro-rehabilitation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1990 Nov;8(11):1777-81 [1700077.001]
  • [Cites] Jpn J Clin Oncol. 2008 Apr;38(4):281-7 [18321891.001]
  • [Cites] J Clin Oncol. 1988 Aug;6(8):1239-47 [2457658.001]
  • [Cites] J Clin Oncol. 1986 Sep;4(9):1405-17 [3528405.001]
  • [Cites] Oncology. 1985;42(5):296-300 [3875817.001]
  • [Cites] Ann Intern Med. 1981 Sep;95(3):288-92 [6168223.001]
  • [Cites] Oncology. 1983;40(5):344-5 [6684745.001]
  • [Cites] Anticancer Drugs. 1994 Dec;5(6):607-14 [7534146.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2169-78 [10811682.001]
  • [Cites] Urol Int. 2000;65(1):43-5 [10965301.001]
  • [Cites] Arq Neuropsiquiatr. 2003 Mar;61(1):129-33 [12715037.001]
  • [Cites] Semin Oncol. 2006 Feb;33(1):121-38 [16473650.001]
  • [Cites] Eur Neurol. 2007;57(2):109-10 [17179715.001]
  • [Cites] Anticancer Drugs. 2008 Jan;19(1):97-8 [18043135.001]
  • [Cites] Ann Intern Med. 1986 Jul;105(1):48-51 [2424354.001]
  • (PMID = 20062719.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2803879
  •  go-up   go-down


Advertisement
4. Lanuke K, Mack LA, Temple WJ: A prospective evaluation of venous thromboembolism in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Can J Surg; 2009 Feb;52(1):18-22
MedlinePlus Health Information. consumer health - Pulmonary Embolism.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective evaluation of venous thromboembolism in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
  • BACKGROUND: We sought to investigate the incidence of perioperative venous thromboembolism (VTE)--pulmonary embolism, superior mesenteris vein thrombosis and deep vein thrombosis--in patients with peritoneal carcinomatosis after cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy.
  • METHODS: We performed cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on 60 consecutive patients with a mean age of 52 (range 24-76) years.
  • We reviewed a prospective database recording complications and patient, tumour and surgical characteristics to determine the incidence of VTE.
  • RESULTS: A total of 6 of 60 patients (10%) who had cytoreductive surgery and hyperthermic intraperitoneal chemotherapy experienced VTE.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion. Digestive System Neoplasms / therapy. Hyperthermia, Induced. Pulmonary Embolism / etiology. Venous Thrombosis / etiology
  • [MeSH-minor] Adenocarcinoma / therapy. Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Incidence. Infusions, Parenteral. Male. Middle Aged. Prospective Studies. Pseudomyxoma Peritonei / therapy. Tachycardia / etiology. Time Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Intern Med. 2000 Mar 27;160(6):809-15 [10737280.001]
  • [Cites] Am J Transplant. 2007 Jan;7(1):185-94 [17227567.001]
  • [Cites] Liver Transpl. 2001 Oct;7(10):896-903 [11679989.001]
  • [Cites] Ann Surg Oncol. 2001 Dec;8(10):787-95 [11776492.001]
  • [Cites] Arch Surg. 2003 Jan;138(1):26-33 [12511145.001]
  • [Cites] Ann Surg Oncol. 2003 Jun;10(5):508-13 [12794016.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3737-43 [14551293.001]
  • [Cites] J Surg Oncol. 2004 Feb;85(2):61-7 [14755505.001]
  • [Cites] Ann Surg Oncol. 2004 Apr;11(4):387-92 [15070598.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):205-13 [15273542.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3284-92 [15310771.001]
  • [Cites] Chest. 2004 Sep;126(3 Suppl):338S-400S [15383478.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):124-32 [7857141.001]
  • [Cites] Ann Surg. 2006 Jan;243(1):89-95 [16371741.001]
  • [Cites] Br J Surg. 2006 Jan;93(1):100-4 [16302177.001]
  • [Cites] Eur J Surg Oncol. 2006 Mar;32(2):186-90 [16303281.001]
  • [Cites] Cancer. 2006 Mar 1;106(5):1144-53 [16456817.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1112-8 [16505431.001]
  • [Cites] Thromb Haemost. 2006 Apr;95(4):752-4 [16601855.001]
  • [Cites] Ann Surg Oncol. 2006 May;13(5):635-44 [16523363.001]
  • [Cites] Curr Opin Pulm Med. 2006 Sep;12(5):291-8 [16926640.001]
  • [Cites] Anesthesiology. 2006 Nov;105(5):1034-46 [17065899.001]
  • [Cites] Eur J Surg Oncol. 2006 Nov;32(9):911-6 [16626920.001]
  • [Cites] J Surg Oncol. 2000 May;74(1):41-4 [10861608.001]
  • (PMID = 19234647.001).
  • [ISSN] 1488-2310
  • [Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie
  • [ISO-abbreviation] Can J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2637643
  •  go-up   go-down


5. Kosugi M, Ono T, Yamaguchi H, Sato N, Dan K, Tanaka K, Takano T: Successful treatment of primary cardiac lymphoma and pulmonary tumor embolism with chemotherapy. Int J Cardiol; 2006 Jul 28;111(1):172-3
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of primary cardiac lymphoma and pulmonary tumor embolism with chemotherapy.
  • A 72-year-old man with a large mass in the right atrium and the pulmonary embolism by chest computed tomography was diagnosed as the primary cardiac B-cell lymphoma (PCL) with pulmonary tumor embolism and pericardial effusion.
  • Upon completion of initial chemotherapy, the mass was markedly reduced, and the pulmonary embolism disappeared on magnetic resonance imaging.
  • This rarely diagnosed entity is treatable with chemotherapy for both PCL and pulmonary embolism.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Heart Neoplasms / drug therapy. Lymphoma, B-Cell / drug therapy. Neoplastic Cells, Circulating. Pulmonary Embolism / drug therapy. Pulmonary Embolism / etiology
  • [MeSH-minor] Aged. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Male. Prednisone / therapeutic use. Remission Induction. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16129500.001).
  • [ISSN] 0167-5273
  • [Journal-full-title] International journal of cardiology
  • [ISO-abbreviation] Int. J. Cardiol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Ireland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


6. Carron M, Ori C: Thrombolysis for massive pulmonary tumour embolism in a patient with cavoatrial renal carcinoma. Br J Anaesth; 2008 Aug;101(2):285-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thrombolysis for massive pulmonary tumour embolism in a patient with cavoatrial renal carcinoma.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Heart Neoplasms / secondary. Neoplastic Cells, Circulating / drug effects. Pulmonary Embolism / drug therapy. Thrombolytic Therapy / methods
  • [MeSH-minor] Humans. Male. Middle Aged. Tissue Plasminogen Activator / therapeutic use

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18614604.001).
  • [ISSN] 1471-6771
  • [Journal-full-title] British journal of anaesthesia
  • [ISO-abbreviation] Br J Anaesth
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.21.68 / Tissue Plasminogen Activator
  •  go-up   go-down


7. Tucakovic M, Bascom R, Bascom PB: Pulmonary medicine and palliative care. Best Pract Res Clin Obstet Gynaecol; 2001 Apr;15(2):291-304
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary medicine and palliative care.
  • Parenchymal metastases are typically multifocal and respond to chemotherapy, with a limited role for pulmonary metastatectomy.
  • Pulmonary tumour embolism is frequently associated with lymphangitic carcinomatosis, and is most common in choriocarcinoma.
  • Opiates are effective at relieving dyspnoea associated with effusions, metatases, and lymphangitic tumour spread.
  • Non-pharmacological therapies include energy conservation, home redesign, and dyspnoea relief strategies, including pursed lip breathing, relaxation, oxygen, circulation of air with a fan, and attention to spiritual suffering.
  • Identification and treatment of gastroesophageal reflux, sinusitis, and asthma can improve many patients' coughs.
  • [MeSH-major] Genital Neoplasms, Female / complications. Genital Neoplasms, Female / therapy. Lung Diseases / etiology. Palliative Care / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Airway Obstruction / therapy. Cough / therapy. Dyspnea / therapy. Female. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Meige Syndrome / surgery. Pleural Effusion, Malignant / therapy. Pulmonary Embolism / diagnosis. Pulmonary Embolism / drug therapy. Quality of Life. Vena Cava Filters

  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Harcourt Publishers Ltd.
  • (PMID = 11358403.001).
  • [ISSN] 1521-6934
  • [Journal-full-title] Best practice & research. Clinical obstetrics & gynaecology
  • [ISO-abbreviation] Best Pract Res Clin Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 65
  •  go-up   go-down


8. Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, Sathornsumetee S, McLendon RE, Herndon JE 2nd, Marcello JE, Norfleet J, Friedman AH, Bigner DD, Friedman HS: Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer; 2009 Dec 15;101(12):1986-94
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.
  • Two patients had asymptomatic, grade 1 intracranial haemorrhage and one on-study death occurred because of pulmonary embolism.
  • Its anti-tumour activity is similar to that of bevacizumab monotherapy or bevacizumab plus irinotecan. (ClinicalTrials.gov: NCT00612430).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Humanized. Bevacizumab. Biomarkers, Tumor / analysis. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Male. Middle Aged. Treatment Failure. Vascular Endothelial Growth Factor A / antagonists & inhibitors

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4899-905 [18794539.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4672-8 [18824714.001]
  • [Cites] J Chemother. 2008 Oct;20(5):632-9 [19028628.001]
  • [Cites] J Neurooncol. 2009 Feb;91(3):329-36 [18953493.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):740-5 [19114704.001]
  • [Cites] Ann Oncol. 2009 Feb;20(2):227-30 [18842611.001]
  • [Cites] J Clin Oncol. 2009 Jun 20;27(18):2905-8 [19451418.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):626-35 [16837971.001]
  • [Cites] J Neurooncol. 2006 Dec;80(3):313-32 [16807780.001]
  • [Cites] Neuro Oncol. 2007 Jan;9(1):29-38 [17108063.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Ann Oncol. 2007 Jun;18(6):1117 [17586751.001]
  • [Cites] Neuro Oncol. 2007 Jul;9(3):354-63 [17452651.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):2993-5 [17634476.001]
  • [Cites] Nat Rev Neurosci. 2007 Aug;8(8):610-22 [17643088.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] J Clin Oncol. 2008 Jan 1;26(1):76-82 [18165643.001]
  • [Cites] Cancer Invest. 2008 Feb;26(1):53-9 [18181046.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):271-8 [18182667.001]
  • [Cites] Neurology. 2008 Mar 4;70(10):779-87 [18316689.001]
  • [Cites] Cancer. 2008 May 15;112(10):2267-73 [18327820.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):162-70 [18356283.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Neoplasia. 2000 Jul-Aug;2(4):306-14 [11005565.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7501-6 [11606386.001]
  • [Cites] Hypertension. 2002 Mar 1;39(3):815-20 [11897770.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6938-43 [12460910.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4342-6 [12907602.001]
  • [Cites] J Hypertens. 2003 Dec;21(12):2297-303 [14654750.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):423-36 [15170445.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3a):1759-63 [15274352.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5):618-34 [15497115.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):2072-6 [7636550.001]
  • [Cites] J Neurooncol. 1996 Feb;27(2):149-55 [8699237.001]
  • [Cites] Arch Neurol. 1999 Jun;56(6):703-8 [10369310.001]
  • [Cites] Circulation. 2005 Feb 15;111(6):796-803 [15699263.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1363-9 [16446323.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Sep;58(3):354-60 [16333676.001]
  • [Cites] Oncol Rep. 2006 Jul;16(1):133-40 [16786136.001]
  • [Cites] J Neurooncol. 2008 Jul;88(3):339-47 [18389177.001]
  • [Cites] J Neurooncol. 2008 Aug;89(1):113-8 [18438609.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):492-507 [18669428.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14(21):7068-73 [18981004.001]
  • (PMID = 19920819.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00612430
  • [Grant] United States / NINDS NIH HHS / NS / P50 NS020023; United States / NCI NIH HHS / CA / P20 CA096890; United States / NCRR NIH HHS / RR / MO1 RR 30; United States / NINDS NIH HHS / NS / 5P50-NS-20023; United States / NCI NIH HHS / CA / 5R37 CA11898; United States / NCI NIH HHS / CA / R37 CA011898
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab; 6PLQ3CP4P3 / Etoposide
  • [Other-IDs] NLM/ PMC2795427
  •  go-up   go-down


9. Sekiyama T, Mizumura K, Kobayashi T, Hayashi S, Tsujino I, Hashimoto S: [A pulmonary tumor embolism which mimicked pulmonary tumor thrombotic microangiopathy caused by uterine cervical cancer]. Nihon Kokyuki Gakkai Zasshi; 2010 Aug;48(8):595-9
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A pulmonary tumor embolism which mimicked pulmonary tumor thrombotic microangiopathy caused by uterine cervical cancer].
  • Pulmonary perfusion scintigraphy showed multiple nonsegmental defects.
  • Histological analysis of the transbronchial lung biopsy specimens obtained from the right lower lobe showed tumor cell embolism and fibrocellular intimal proliferation, but no thrombus formation or recanalization in the small arteries.
  • On the basis of these findings, we diagnosed pulmonary tumor embolism, not pulmonary tumor thrombotic microangiopathy (PTTM), because the pathological findings did not reveal either thrombus formation or recanalization, and the patient did not show hemodynamic effects such as hemolytic anemia, severe pulmonary hypertension, or disseminated intravascular coagulation.
  • Her symptoms improved after the administration of chemotherapy and radiation therapy.
  • Furthermore, the multiple nonsegmental defects observed on pulmonary perfusion scintigraphy disappeared.
  • Generally, a diagnosis of pulmonary tumor embolism and PTTM is difficult to establish in living patients.
  • It is important that therapy is started before the disease progresses to PTTM, if pulmonary tumor embolism is diagnosed.
  • [MeSH-major] Lung / pathology. Lung Diseases / diagnosis. Neoplastic Cells, Circulating / pathology. Thrombotic Microangiopathies / diagnosis. Uterine Cervical Neoplasms / complications
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged


10. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Köhne CH: Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol; 2010 Jan;11(1):38-47
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
  • BACKGROUND: Neoadjuvant chemotherapy for unresectable colorectal liver metastases can downsize tumours for curative resection.
  • We assessed the effectiveness of cetuximab combined with chemotherapy in this setting.
  • Patients with resectable disease were offered liver surgery within 4-6 weeks of the last treatment cycle.
  • The primary endpoint was tumour response assessed by Response Evaluation Criteria In Solid Tumours (RECIST), analysed by modified intention to treat.
  • A retrospective, blinded surgical review of patients with radiological images at both baseline and during treatment was done to assess objectively any changes in resectability.
  • One patient in each group were excluded from the analysis of the primary endpoint because they discontinued treatment before first full dose, one patient in group B was excluded because of early pulmonary embolism.
  • In a retrospective analysis of response by KRAS status, a partial or complete response was noted in 47 (70%) of 67 patients with KRAS wild-type tumours versus 11 (41%) of 27 patients with KRAS-mutated tumours (OR 3.42, 1.35-8.66; p=0.0080).
  • According to the retrospective review, resectability rates increased from 32% (22 of 68 patients) at baseline to 60% (41 of 68) after chemotherapy (p<0.0001).
  • INTERPRETATION: Chemotherapy with cetuximab yields high response rates compared with historical controls, and leads to significantly increased resectability.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / pathology. Hepatectomy. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Humanized. Austria. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Cetuximab. Chemotherapy, Adjuvant. Female. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Germany. Humans. Leucovorin / adverse effects. Leucovorin / therapeutic use. Linear Models. Magnetic Resonance Imaging. Male. Middle Aged. Mutation. Neoadjuvant Therapy. Odds Ratio. Organoplatinum Compounds / adverse effects. Organoplatinum Compounds / therapeutic use. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins B-raf / genetics. Receptor, Epidermal Growth Factor / analysis. Retrospective Studies. Risk Assessment. Time Factors. Tomography, Spiral Computed. Treatment Outcome. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • [CommentIn] Lancet Oncol. 2010 Apr;11(4):313-4; author reply 314 [20359660.001]
  • [CommentIn] Lancet Oncol. 2010 Jan;11(1):4-5 [19942480.001]
  • [CommentIn] Lancet Oncol. 2010 Feb;11(2):116 [20152768.001]
  • (PMID = 19942479.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00153998
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / KRAS protein, human; 0 / Organoplatinum Compounds; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins; PQX0D8J21J / Cetuximab; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; Folfox protocol; IFL protocol
  •  go-up   go-down


11. Peiffert D, Giovannini M, Ducreux M, Michel P, François E, Lemanski C, Mirabel X, Cvitkovic F, Luporsi E, Conroy T, Gérard JP, Digestive Tumours Group of the French 'Fédération Nationale des Centres de Lutte Contre le Cancer': High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: final results of a phase II study. Ann Oncol; 2001 Mar;12(3):397-404
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: final results of a phase II study.
  • PURPOSE: To analyse toxicity and response to a new scheme of neoadjuvant chemotherapy (CT) and concomitant radiochemotherapy (RT-CT) for locally advanced anal canal squamous-cell carcinoma (ACC).
  • Pelvic (+/- inguinal) RT delivered 45 Gy in 25 fractions of 1.8 Gy.
  • Involved fields were boosted after a one to two month gap (15-20 Gy).
  • RESULTS: One patient died of a pulmonary embolism on day 4.
  • All patients received the entire treatment, with reduced 5-FU doses in 27% of the cases because of acute toxicity.
  • Complete response (CR) and partial response (PR) rates were, respectively, 10% and 51% after neoadjuvant CT, 67% and 28% after RT-CT and 93% and 5% after treatment completion (including 4 abdomino-perineal resections).
  • The three-year actuarial overall, tumour-specific, colostomy-free, relapse-free, disease-free and event-free survivals were 86%, 88%, 73%, 70%, 67% and 63%, respectively.
  • After treatment completion, all but five achieved CR.

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11332154.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Marmol M, Pomes J, Muñoz M, Macho J, Blasco J, Combalia A, Farrus B, Verger E, Tomàs X, Gascon P: Vertebroplastia in patients with tumour injury of the vertebral body; therapeutic effect and short term complications. J Clin Oncol; 2004 Jul 15;22(14_suppl):8263

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vertebroplastia in patients with tumour injury of the vertebral body; therapeutic effect and short term complications.
  • : 8263 Background: Metastatic involvement of vertebral columnae affects performance status (PS) of cancer patients (pts) and compromise the efficacy of treatment.
  • Radiotherapy and surgical management are therapeutical options to relieve tumour pain. (VP) can also be an effective modality to treat injured vertebrae.
  • Our objectives were to analyse the clinical benefit of VP: in avoiding the interruption or delay of the chemotherapy treatment and to obtain pain relief without complications.
  • Seven pts (46%) were able to start or follow chemotherapy treatment in the next 24 hours after procedure.
  • There was a complication in the form of one case of pulmonary embolism.
  • CONCLUSIONS: VP is an effective procedure for treating pain in patients with vertebral body tumour injury and, it appears to have an excellent safety profile.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016713.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Bozaci EA, Taşkin S, Gürkan O, Atasoy C, Ersoy ZG, Erekul S, Numanoğlu N, Ortaç F: Intracavitary cardiac metastasis and pulmonary tumor emboli of choriocarcinoma: the first case diagnosed and treated without surgical intervention. Gynecol Oncol; 2005 Dec;99(3):753-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracavitary cardiac metastasis and pulmonary tumor emboli of choriocarcinoma: the first case diagnosed and treated without surgical intervention.
  • Its pulmonary tumor embolism and cardiac metastasis are very rarely encountered, of which antemortem diagnosis is even more rare.
  • CASE: To our knowledge, we present the first case of intracavitary cardiac metastasis and pulmonary tumor emboli of choriocarcinoma diagnosed and treated without any surgical intervention.
  • Multi-agent chemotherapy led to almost complete regression of cardiac and pulmonary lesions and normalization of beta-hCG levels.
  • As the tumor is highly sensitive, chemotherapy together with biochemical and radiological monitoring constitutes an effective treatment modality if cardiopulmonary functions are not deteriorating.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Choriocarcinoma / drug therapy. Choriocarcinoma / secondary. Heart Neoplasms / drug therapy. Heart Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115666.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Correale P, Cerretani D, Remondo C, Martellucci I, Marsili S, La Placa M, Sciandivasci A, Paolelli L, Pascucci A, Rossi M, Di Bisceglie M, Giorgi G, Gotti G, Francini G: A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients. Oncol Rep; 2006 Jul;16(1):133-40
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients.
  • The aim of this pilot phase II trial was to investigate the toxicity and anti-tumour activity of a novel metronomic regimen of weekly cisplatin (CDDP) and oral etoposide (VP16) in high-risk patients with advanced NSCLC.
  • The most frequent adverse events were grade III leukopenia and anemia; nevertheless, three patients died of pulmonary embolism after 2, 3 and 6 weeks of treatment.
  • The mean time to progression and survival were respectively nine months (95% CI, 6.3-15.8 months) and thirteen months (95% CI, 9.1-20.5 months).
  • Pharmacological analysis showed that this metronomic regimen allows a much greater median monthly area under the curve of CDDP and VP16 than conventional treatment schedules.
  • Our findings also suggest that this treatment schedule may affect tumour growth and neoangiogenesis by changing peripheral blood vascular-endothelial growth factor levels.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Cisplatin / administration & dosage. Etoposide / administration & dosage. Lung Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Aged. Aged, 80 and over. Drug Administration Schedule. Female. Humans. Male. Middle Aged


15. Barton SJ, Ashdown DA, Ganta S, Wallace D: An unusual presentation of metastatic testicular tumour. J R Army Med Corps; 2005 Mar;151(1):30-3
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual presentation of metastatic testicular tumour.
  • We report a unique case of metastatic malignant teratoma from an undescended testis which presented with acute pulmonary embolism.
  • After chemotherapy, the undescended right testicle was resected along with a cord of non- obstructing inferior venal caval tumour which extended into the right atrium with tumour floating free within the atrium at the end of the cord of tumour.
  • The presentation, diagnosis and treatment of testicular tumours is described and the literature pertaining to testicular tumours in military personnel reviewed.
  • [MeSH-major] Carcinoma, Embryonal / diagnosis. Pulmonary Embolism / diagnosis. Pulmonary Embolism / etiology. Teratoma / diagnosis. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Humans. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Male. Military Personnel. Neoplastic Cells, Circulating. Vascular Neoplasms / diagnosis. Vascular Neoplasms / secondary. Vascular Neoplasms / surgery. Vena Cava, Inferior / pathology. Venous Thrombosis / diagnosis. Venous Thrombosis / surgery

  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15912681.001).
  • [ISSN] 0035-8665
  • [Journal-full-title] Journal of the Royal Army Medical Corps
  • [ISO-abbreviation] J R Army Med Corps
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


16. El Fekih L, Hassene H, Fenniche S, Ben Abdelghaffar H, Belhabib D, Megdiche ML: Pulmonary metastases revealing choriocarcinoma. Tunis Med; 2010 Jan;88(1):49-51
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary metastases revealing choriocarcinoma.
  • BACKGROUND: Uterin choriocarcinoma is a trophoblastic tumour characterised by high metastasis potential.
  • A diagnosis of metastatic choriocarcinoma was confirmed by plasmatic level of beta human chorionic gonadotrophin (beta HCG) superior to 4000 UI/ml.
  • Patient died after 3 cures of chemotherapy because of acute respiratory failure caused by massive pulmonary embolism.
  • CONCLUSION: Diagnosis of choriocarcinoma must be evocated in front of several pulmonary opacities occurring in genital activity women and necessities the dosage of level of BHCG.
  • [MeSH-major] Biomarkers, Tumor / blood. Choriocarcinoma / secondary. Chorionic Gonadotropin, beta Subunit, Human / blood. Lung Neoplasms / secondary. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Fatal Outcome. Female. Hemoptysis / etiology. Humans. Postpartum Period. Pregnancy. Prognosis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20415215.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Tunisia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


17. Longhi A, Rimondi E, Loro L, Tetta C, Rossi G, DeBenedittis M, Bacci G: Pulmonary nodules in osteosarcoma patients: differential diagnosis of central venous catheter-related infections in the lungs. Radiol Med; 2006 Mar;111(2):192-201
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary nodules in osteosarcoma patients: differential diagnosis of central venous catheter-related infections in the lungs.
  • PURPOSE: The purpose of this study was to evaluate the differential diagnosis of pulmonary nodules by conventional radiography and computed tomography (CT) in osteosarcoma patients with central venous catheter.
  • MATERIALS AND METHODS: Between March 1997 and December 2001 at our Department of Musculoskeletal Oncology, 231 patients with peripheral osteosarcoma received a central venous catheter to allow infusion therapy and blood sampling.
  • All patients underwent radiological investigation for tumour staging and comparison with the following study in accordance with the protocol in place at our Department of Oncology and Division of Diagnostic Imaging.
  • RESULTS: Of a total of 231 patients, 13 (5.6%) developed an infection of the central venous line, with fever that was very high in some cases.
  • After appropriate antibiotic and replacement of the central venous line, CT demonstrated disappearance of the lung nodules in all three patients, enabling a diagnosis of nodular septic embolism.
  • CONCLUSIONS: Placement of a central venous catheter for infusion therapy, chemotherapy and blood sampling has improved the quality of life of cancer patients.
  • The most common complications of the use of central venous catheters include infection and venous thrombosis whereas pulmonary septic emboli are rare.
  • [MeSH-major] Bacterial Infections / radiography. Bone Neoplasms / drug therapy. Catheterization, Central Venous / instrumentation. Catheters, Indwelling / adverse effects. Lung Diseases / radiography. Osteosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Anti-Bacterial Agents / therapeutic use. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Pneumonia, Bacterial / radiography. Pulmonary Alveoli / radiography. Pulmonary Embolism / radiography. Sepsis / radiography. Tomography, X-Ray Computed


18. Seiz M, Kohlhof P, Brockmann MA, Neumaier-Probst E, Hermes P, VON Deimling A, Vajkoczy P, Schmieder K, Tuettenberg J: First experiences with low-dose anti-angiogenic treatment in gliomatosis cerebri with signs of angiogenic activity. Anticancer Res; 2009 Aug;29(8):3261-7
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First experiences with low-dose anti-angiogenic treatment in gliomatosis cerebri with signs of angiogenic activity.
  • BACKGROUND: Gliomatosis cerebri is a rare primary cerebral tumour entity characterized by diffuse infiltrative growth patterns representing a WHO grade III malignancy.
  • It was therefore decided to administer continuous low-dose chemotherapy with temozolomide and celecoxib for antiangiogenic treatment in the four patients that were in good clinical condition following external radiotherapy.
  • RESULTS: In all patients, treatment was well tolerated and MRI follow-up showed no tumour progression for at least six months.
  • One patient died due to pulmonary embolism 9 months after diagnosis; another patient survived 15 months after diagnosis with progressive disease in the last follow-up MRI before death.
  • Two other patients at the present time are still in a stable clinical condition without signs of tumour progression in MRI (12 and 18 months).
  • CONCLUSION: From our initial experience in a small number of patients with gliomatosis cerebri with signs of angiogenic activity, we conclude that low-dose chemotherapy might provide a promising approach for treatment of these patients and that overexpression of angiogenic factors such as VEGF or COX-2 seems to be more frequent than hitherto reported.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Neuroepithelial / blood supply. Neoplasms, Neuroepithelial / drug therapy. Neovascularization, Pathologic / prevention & control
  • [MeSH-minor] Adult. Aged. Celecoxib. Cell Proliferation. Cyclooxygenase 2 / metabolism. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Disease Progression. Dose-Response Relationship, Drug. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. Pyrazoles / administration & dosage. Sulfonamides / administration & dosage. Survival Rate. Vascular Endothelial Growth Factor A / metabolism

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661344.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Pyrazoles; 0 / Sulfonamides; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


19. Castelli R, Ferrari B, Cortelezzi A, Guariglia A: Thromboembolic complications in malignant haematological disorders. Curr Vasc Pharmacol; 2010 Jul;8(4):482-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The vast majority of patients with haematological neoplasias also have clinically silent haemostatic abnormalities, but some may show clinical manifestations, including venous thromboembolism, pulmonary embolism, disseminated intravascular coagulation and life-threatening thrombohaemorrhagic syndrome in acute leukaemias.
  • The pathogenesis of thromboembolic disease in haematological malignancies is complex and multifactorial: tumour cell-derived procoagulant, fibrinolytic or proteolytic factors and inflammatory cytokines affect clotting activation, and chemotherapy and anti-angiogenic drugs increase thrombotic risk in patients with lymphoma, acute leukaemia and multiple myeloma.
  • Infectious complications are another important factor: endotoxins from gram-negative bacteria induce the release of tissue factor (TF), Tumor Necrosis Factor (TNF) and interleukin-1b (IL-1b), and gram-positive organisms can release bacterial mucopolysaccharides that directly activate factor XII.
  • Leukaemic patients may be affected by other prothrombotic factors, including hyperleukocytosis, increased TF expression and activation, and the prothrombotic properties of therapeutic agents such as all-trans retinoic acid and L-asparaginase, which can induce thrombosis involving multiple organs.
  • The very high risk of haemorrhaging in these patients warrants prospective randomised trials evaluating optimal anti-thrombotic prophylaxis and treatment.
  • [MeSH-major] Hematologic Neoplasms / complications. Hematologic Neoplasms / drug therapy. Thromboembolism / drug therapy. Thromboembolism / etiology
  • [MeSH-minor] Bone Marrow Transplantation / adverse effects. Drug Therapy, Combination. Hemorheology / physiology. Humans. Leukemia / drug therapy. Leukemia / metabolism. Leukemia / physiopathology. Leukocytosis / physiopathology. Paraproteinemias / complications. Paraproteinemias / drug therapy. Paraproteinemias / physiopathology. Pulmonary Embolism / drug therapy. Pulmonary Embolism / etiology. Pulmonary Embolism / physiopathology. Risk Factors. Thrombotic Microangiopathies / etiology. Thrombotic Microangiopathies / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19485900.001).
  • [ISSN] 1875-6212
  • [Journal-full-title] Current vascular pharmacology
  • [ISO-abbreviation] Curr Vasc Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United Arab Emirates
  • [Number-of-references] 148
  •  go-up   go-down


20. Heidrich H, Konau E, Hesse P: Asymptomatic venous thrombosis in cancer patients--a problem often overlooked. Results of a retrospective and prospective study. Vasa; 2009 May;38(2):160-6
MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Venous thrombosis with and without pulmonary embolism is a frequent complication of malignancies and second among the causes of death in tumour patients.
  • Since for methodological reasons, this rate can be assumed to be too low and to disregard asymptomatic venous thrombosis, a combined retrospective and prospective study was performed to examine the actual frequency of venous thrombosis in tumour patients.
  • PATIENTS AND METHODS: The histories of 409 patients (175 women, 234 men, mean age 69 years [19 to 96 years]) with different tumours, consecutively enrolled in the order of their altogether 426 inpatient treatments, were checked in retrospect for the frequency of venous thrombosis and pulmonary embolism.
  • Subsequently, 97 tumour inpatients (36 women, 61 men, mean age 70 years [42 to 90 years]) were systematically screened, by means of duplex sonography and/or venography, for venous thromboses in the veins of the pelvis and both legs.
  • RESULTS: In the retrospective analysis, where no systematic screening for thromboses was performed and only symptomatic thrombosis was recorded, venous thrombosis was found in 6.6% of all tumour patients, whereas in the prospective examination with systematic duplex sonography and / or venography of all patients, the percentage was 33%.
  • In 39.3% of the cases in the retrospective analysis and 25% in the prospective analysis, venous thrombosis occurred during chemotherapy, surgery or radiation therapy.
  • CONCLUSION: Regular screening for thrombosis is indicated even in asymptomatic tumour patients because asymptomatic venous thrombosis is frequent, can lead to pulmonary embolism and has to be treated like symptomatic venous thrombosis.
  • This is particularly true for metastasization during chemotherapy, surgical interventions, or radiation.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Comorbidity. Cross-Sectional Studies. Female. Germany. Humans. Male. Mass Screening. Middle Aged. Phlebography. Prospective Studies. Pulmonary Embolism / diagnosis. Pulmonary Embolism / epidemiology. Retrospective Studies. Risk Factors. Ultrasonography, Doppler, Duplex. Young Adult

  • Genetic Alliance. consumer health - Thrombosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19588304.001).
  • [ISSN] 0301-1526
  • [Journal-full-title] VASA. Zeitschrift für Gefässkrankheiten
  • [ISO-abbreviation] VASA
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


21. Pérol M, Arpin D: [Bevacizumab and non-small cell lung cancer: a new step?]. Rev Mal Respir; 2009 Feb;26(2):125-38
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inhibition of specific processes essential for tumour vascular development is one of the key strategies for the treatment of non- small cell lung cancer (NSCLC).
  • Combination of bevacizumab with standard first-line chemotherapy in NSCLC leads to an improvement in response rates and progression-free survival compared to chemotherapy alone and a significant survival advantage with carboplatin- paclitaxel chemotherapy.
  • Toxicity issues are of concern with the possible occurrence of hypertension and an increased risk of arterial thrombo-embolism.
  • The occurrence of fatal pulmonary haemorrhage after necrosis of the primary tumour is a specific toxicity in NSCLC which requires appropriate selection of patients before treatment; excluding squamous cell carcinoma, haemorrhagic tumours and tumour invasion of major blood vessels.
  • The use of bevacizumab combined with chemotherapy represent a first step in the development of antiangiogenic treatments in NSCLC, with the future possibility of using it in earlier stages of disease.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antineoplastic Agents / therapeutic use. Bevacizumab. Clinical Trials, Phase III as Topic. Drug Therapy, Combination. Humans. Vascular Endothelial Growth Factor A / antagonists & inhibitors

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19319108.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


22. Cunningham MS, Preston RJ, O'Donnell JS: Does antithrombotic therapy improve survival in cancer patients? Blood Rev; 2009 May;23(3):129-35
Hazardous Substances Data Bank. WARFARIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does antithrombotic therapy improve survival in cancer patients?
  • Anticoagulant therapy, in the form of heparin and warfarin, plays an important role in the prevention of recurrent VTE.
  • Recent studies have demonstrated that long-term therapy with low molecular weight heparin (LMWH) is more effective than warfarin in patients with cancer.
  • Intriguingly, however, this improved survival cannot simply be explained by a reduction in fatal pulmonary embolism.
  • Furthermore, the beneficial effects persist long after the LMWH has been discontinued, suggesting that LMWH can directly influence tumour cell biology.
  • This hypothesis is entirely plausible, given the complex feedback mechanisms that exist between tumour cells, coagulation proteases, and vascular endothelial cells.
  • Further large randomized controlled trials will be required in order to validate these exciting preliminary data, and to define whether anticoagulant therapy may constitute a useful adjunctive therapy in the management of cancer patients without VTE.
  • [MeSH-major] Anticoagulants / therapeutic use. Heparin, Low-Molecular-Weight / therapeutic use. Neoplasms / mortality. Venous Thromboembolism / drug therapy. Warfarin / therapeutic use

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19046797.001).
  • [ISSN] 1532-1681
  • [Journal-full-title] Blood reviews
  • [ISO-abbreviation] Blood Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Heparin, Low-Molecular-Weight; 5Q7ZVV76EI / Warfarin
  • [Number-of-references] 75
  •  go-up   go-down


23. Wellington K, Faulds DM: Anastrozole: in early breast cancer. Drugs; 2002;62(17):2483-90; discussion 2491-2
Hazardous Substances Data Bank. ANASTROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anastrozole, a nonsteroidal selective aromatase inhibitor, has recently been approved in the US and several other countries for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer.
  • In the Arimidex, Tamoxifen alone or in Combination (ATAC) trial, anastrazole 1mg was significantly more effective than tamoxifen 20mg or combined treatment (17 and 19% relative risk reduction) for disease-free survival in postmenopausal women with early breast cancer. black triangle Anastrazole was also significantly more effective than tamoxifen for time to tumour recurrence and the odds of a primary contralateral tumour as a first event.
  • During the first 2 years of treatment with anastrozole, tamoxifen or the combination, patient quality of life was similar in all treatment groups.
  • Compared with tamoxifen, anastrozole was associated with a significantly lower incidence of vaginal bleeding, vaginal discharge, hot flushes, endometrial cancer, ischaemic cerebrovascular events, venous thromboembolic events and deep vein thrombosis including pulmonary embolism; tamoxifen was associated with a lower incidence of musculoskeletal disorders and fracture.
  • [MeSH-major] Aromatase Inhibitors. Breast Neoplasms / drug therapy. Enzyme Inhibitors / therapeutic use. Neoplasm Recurrence, Local. Nitriles / therapeutic use. Triazoles / therapeutic use
  • [MeSH-minor] Administration, Oral. Antineoplastic Agents, Hormonal / therapeutic use. Chemotherapy, Adjuvant. Disease-Free Survival. Drug Therapy, Combination. Female. Half-Life. Humans. Neoplasm Staging. Randomized Controlled Trials as Topic. Tamoxifen / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 2000;46(1):35-9 [10912575.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1230-6 [11350888.001]
  • [Cites] Lancet. 2002 Jun 22;359(9324):2131-9 [12090977.001]
  • [Cites] Br J Cancer. 2001 Aug 3;85(3):317-24 [11487258.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):751-7 [11821457.001]
  • [Cites] Br J Cancer. 1996 Oct;74(8):1286-91 [8883419.001]
  • [Cites] Drugs Aging. 1998 Oct;13(4):321-32 [9805213.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2620-35 [11555572.001]
  • [Cites] Br J Cancer. 1996 Feb;73(4):543-8 [8595172.001]
  • [Cites] Br J Cancer. 2002 Oct 21;87(9):950-5 [12434282.001]
  • [Cites] Breast Cancer Res Treat. 1994;30(1):103-11 [7949201.001]
  • [Cites] Br J Cancer. 1998 Sep;78 Suppl 4:16-20 [9741784.001]
  • (PMID = 12421108.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Aromatase Inhibitors; 0 / Enzyme Inhibitors; 0 / Nitriles; 0 / Triazoles; 094ZI81Y45 / Tamoxifen; 2Z07MYW1AZ / anastrozole
  • [Number-of-references] 20
  •  go-up   go-down


24. Lenalidomide: new drug. Myeloma: many questions remain unanswered. Prescrire Int; 2008 Dec;17(98):230-2
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lenalidomide: new drug. Myeloma: many questions remain unanswered.
  • (2) Lenalidomide, a structural analogue of thalidomide, is licensed for the treatment of multiple myeloma, in combination with dexamethasone, after failure of the initial treatment regimen;.
  • When this combination was used, the median time to tumour progression was 11 months.
  • In clinical trials, the median time to tumour progression was about 2 years with thalidomide and 8 months with bortezomib;.
  • (5) In clinical trials, lenalidomide, like thalidomide, provoked deep venous thrombosis (9% versus 4% with placebo) and pulmonary embolism (4% versus 1%).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Multiple Myeloma / drug therapy. Thalidomide / analogs & derivatives. Thalidomide / therapeutic use
  • [MeSH-minor] Dexamethasone / administration & dosage. Dexamethasone / adverse effects. Dexamethasone / therapeutic use. Drug Approval. Drug Therapy, Combination. France. Humans. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19422142.001).
  • [ISSN] 1167-7422
  • [Journal-full-title] Prescrire international
  • [ISO-abbreviation] Prescrire Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 4Z8R6ORS6L / Thalidomide; 7S5I7G3JQL / Dexamethasone; F0P408N6V4 / lenalidomide
  •  go-up   go-down


25. Gagel B, Reinartz P, Demirel C, Kaiser HJ, Zimny M, Piroth M, Pinkawa M, Stanzel S, Asadpour B, Hamacher K, Coenen HH, Buell U, Eble MJ: [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer; 2006;6:51
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study.
  • BACKGROUND: Experimental and clinical evidence suggest that hypoxia in solid tumours reduces their sensitivity to conventional treatment modalities modulating response to ionizing radiation or chemotherapeutic agents.
  • The aim of the present study was to show the feasibility of determining radiotherapeutically relevant hypoxia and early tumour response by ([18F] Fluoromisonidazole (FMISO) and [18F]-2-fluoro-2'-deoxyglucose (FDG) PET.
  • Tumour tissue oxygenation was measured with FMISO PET, whereas tumour glucose metabolism was measured with FDG PET.
  • The patients were treated with chemotherapy, consisting of 2 cycles of gemcitabine (1200 mg/m2) and vinorelbine (30 mg/m2) followed by concurrent radio- (2.0 Gy/d; total dose 66.0 Gy) and chemotherapy with gemcitabine (300-500 mg/m2) every two weeks.
  • FMISO PET and FDG PET were performed in all patients 3 days before and 14 days after finishing chemotherapy.
  • In addition, changes in FMISO and FDG PET measure the early response to therapy, and in this way, may predict freedom from disease, as well as overall survival.
  • If confirmed, several novel treatment strategies may be considered, including the early use of PET to evaluate the effectiveness of the selected therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Fluorodeoxyglucose F18. Lung Neoplasms / radionuclide imaging. Misonidazole / analogs & derivatives. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Adult. Arrhythmias, Cardiac / chemically induced. Cell Hypoxia. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Feasibility Studies. Female. Glucose / metabolism. Humans. Lymphatic Metastasis / radionuclide imaging. Male. Maximum Tolerated Dose. Middle Aged. Prospective Studies. Pulmonary Embolism / etiology. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Radiat Oncol. 2001 Jan;11(1):47-57 [11146042.001]
  • [Cites] J Nucl Med. 2005 Feb;46(2):253-60 [15695784.001]
  • [Cites] J Clin Oncol. 2003 Feb 1;21(3):428-32 [12560430.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1358-62 [12654448.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1285-92 [12663716.001]
  • [Cites] Strahlenther Onkol. 2003 Aug;179(8):521-6 [14509950.001]
  • [Cites] Strahlenther Onkol. 2003 Aug;179(8):527-34 [14509951.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jul 1;59(3):822-33 [15183486.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):3-7 [15337533.001]
  • [Cites] Strahlenther Onkol. 2004 Oct;180(10):616-22 [15480509.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Nov;17(5):985-91 [2808061.001]
  • [Cites] J Comput Assist Tomogr. 1990 May-Jun;14(3):370-4 [2335602.001]
  • [Cites] Res Exp Med (Berl). 1991;191(1):27-35 [2034887.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Sep 30;27(2):455-64 [8407422.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1995 Mar;121(3):272-6 [7873142.001]
  • [Cites] Eur J Nucl Med. 1995 Mar;22(3):265-80 [7789400.001]
  • [Cites] Eur J Cancer. 1995 Nov;31A(12):1924-7 [8562143.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):700-8 [8622014.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4509-15 [8813149.001]
  • [Cites] Nuklearmedizin. 1997 Oct;36(7):228-33 [9441281.001]
  • [Cites] Strahlenther Onkol. 2002 Dec;178(12):727-31 [12491062.001]
  • (PMID = 16515707.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0W860991D6 / Deoxycytidine; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 13551-89-8 / fluoromisonidazole; 5V9KLZ54CY / Vinblastine; 8FE7LTN8XE / Misonidazole; B76N6SBZ8R / gemcitabine; IY9XDZ35W2 / Glucose; Q6C979R91Y / vinorelbine
  • [Other-IDs] NLM/ PMC1456976
  •  go-up   go-down


26. Khorana AA, Fine RL: Pancreatic cancer and thromboembolic disease. Lancet Oncol; 2004 Nov;5(11):655-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancreatic-cancer cells activate platelets and express several procoagulant factors, including tissue factor and thrombin.
  • The activation of coagulation is not simply an epiphenomenon, but might also be related to enhanced tumour growth and angiogenesis.
  • Clinical manifestations of thromboembolic disease in pancreatic cancer include deep venous thrombosis, pulmonary embolism, disseminated intravascular coagulation, portal vein thrombosis, and arterial thromboembolism.
  • Treatment options include warfarin and low-molecular-weight heparins.
  • Further research is needed to understand better the morbidity and mortality associated with this disease in pancreatic cancer and to optimise strategies of prevention and treatment.
  • [MeSH-major] Pancreatic Neoplasms / complications. Thromboembolism / drug therapy. Thromboembolism / etiology
  • [MeSH-minor] Anticoagulants / therapeutic use. Heparin, Low-Molecular-Weight / therapeutic use. Humans. Neovascularization, Pathologic. Warfarin / therapeutic use

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. WARFARIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15522652.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Heparin, Low-Molecular-Weight; 5Q7ZVV76EI / Warfarin
  • [Number-of-references] 69
  •  go-up   go-down


27. Sotolongo Vergo I, Suárez Cabrera RE, Arencibia García J: [Retroperitoneal fibrosarcoma. Apropos of a case]. Arch Esp Urol; 2003 May;56(4):421-4
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CT scan confirmed a left flank tumor with internal necrosis which displaced the kidney.
  • Complete tumour resection was performed confirmatory of the histological diagnosis of retroperitoneal fibrosarcoma.
  • Postoperative chemotherapy was administered.
  • Necropsy revealed right pulmonary thromboembolism, abdominal ganglionar metastases and retroperitoneal tumour extension.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Back Pain / etiology. Calcinosis / etiology. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Fatal Outcome. Hematuria / etiology. Humans. Lung Neoplasms / complications. Lung Neoplasms / secondary. Male. Methotrexate / administration & dosage. Middle Aged. Neoplasm Recurrence, Local. Pulmonary Embolism / etiology

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12830615.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


28. Joung S, Robinson B: Venous thromboembolism in cancer patients in Christchurch, 1995-1999. N Z Med J; 2002 Jun 7;115(1155):257-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The clinical records of Christchurch Hospital were searched for all patients with a history of deep venous thrombosis (DVT) and/or pulmonary embolism (PE) between January 1995 and December 1999, who were registered with the Oncology Service.
  • 70% of patients with VTE had one or more risk factors in addition to their malignancy: previous VTE (8%), tumour compression (7%), hospitalisation at the time of VTE diagnosis (23%), chemotherapy (25%), radiotherapy (21 %), hormonal therapy (10%), surgery (8%).
  • The median survival time was 5.2 months for DVT and three months for PE.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Incidence. Male. Medical Records. Middle Aged. New Zealand / epidemiology. Prevalence. Pulmonary Embolism / etiology. Pulmonary Embolism / mortality. Retrospective Studies. Risk Factors. Survival Analysis

  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12117159.001).
  • [ISSN] 0028-8446
  • [Journal-full-title] The New Zealand medical journal
  • [ISO-abbreviation] N. Z. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  •  go-up   go-down


29. Valente M, Pozzi-Mucelli F, Ponte E: Venous thromboembolism and melanoma. Minerva Cardioangiol; 2001 Oct;49(5):327-33
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clotting system may be activated because of enhanced platelet aggregation and adhesion or by stimulation from the endothelial cells or the tumour cells themselves.
  • Furthermore, thrombosis may develop as a result of prolonged immobilization, surgery, chemotherapy or hormone therapy.
  • We present a case of a patient who underwent surgery for excision of a Clark level II melanoma on the back who developed pulmonary metastasis four years after the operation.
  • The metastasis manifested with very severe venous thromboembolism which, despite anticoagulant therapy and the placement of a vena caval filter, led to the patient's death from pulmonary embolism.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11533552.001).
  • [ISSN] 0026-4725
  • [Journal-full-title] Minerva cardioangiologica
  • [ISO-abbreviation] Minerva Cardioangiol
  • [Language] eng; ita
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


30. Bellmunt J, Trigo JM, Calvo E, Carles J, Pérez-Gracia JL, Rubió J, Virizuela JA, López R, Lázaro M, Albanell J: Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). Lancet Oncol; 2010 Apr;11(4):350-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Maximum tolerated dose (MTD) chemotherapy followed by metronomic chemotherapy (low doses given on a frequent schedule) acts on tumour vascular endothelial cells by increasing the anti-tumour effect of anti-angiogenic agents.
  • This multicentre, phase 2 study investigated the effectiveness of MTD gemcitabine combined with metronomic capecitabine plus the multikinase inhibitor sorafenib for the treatment of metastatic renal-cell carcinoma (RCC).
  • Patients were aged 18 years or older, had confirmed metastatic RCC with clear-cell histology, had an Eastern Cooperative Oncology Group performance status of 0 or 1, had not undergone previous therapy, and were unsuitable for, or intolerant to, immunotherapy.
  • Treatment consisted of intravenous gemcitabine 1000 mg/m(2) (days 1 and 8), oral capecitabine 500 mg/m(2) twice a day (final dose after adjustment, days 1-14), and oral sorafenib 400 mg twice a day (days 1-21), for six cycles, followed by sorafenib monotherapy (at the investigator's discretion if clinical benefit was maintained).
  • The primary endpoint was median progression-free survival (PFS) analysed in a population of all patients who received treatment.
  • FINDINGS: 44 patients enrolled in the study, 40 of whom received treatment.
  • One death due to pulmonary embolism was reported as grade 5 dyspnoea possibly related to study drug.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Benzenesulfonates / administration & dosage. Benzenesulfonates / adverse effects. Benzenesulfonates / pharmacology. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Deoxycytidine / pharmacology. Drug Administration Schedule. Drug Synergism. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / analogs & derivatives. Fluorouracil / pharmacology. Humans. Male. Maximum Tolerated Dose. Middle Aged. Niacinamide / analogs & derivatives. Phenylurea Compounds. Pyridines / administration & dosage. Pyridines / adverse effects. Pyridines / pharmacology. Survival Analysis

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • [CommentIn] Lancet Oncol. 2010 Apr;11(4):307-8 [20359658.001]
  • (PMID = 20163987.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00496301
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 0W860991D6 / Deoxycytidine; 25X51I8RD4 / Niacinamide; 6804DJ8Z9U / Capecitabine; 9ZOQ3TZI87 / sorafenib; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


31. Smith SF, Simpson JM, Sekhon LH: A quarter of a century of neurosurgery: the value of a relational database to document trends in neurosurgical practice of a tertiary referral hospital. J Clin Neurosci; 2004 Jan;11(1):31-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mean age increased significantly for tumour, trauma and spinal patients; geometric mean LOS declined significantly for tumour, spine, vascular, cranial nerve and peripheral nerve groups.
  • Concurrently, inpatient death rate fell significantly for tumour and vascular patients.
  • Deep vein thrombosis (DVT) rose significantly for trauma, vascular, tumour, spinal and infection patients; pulmonary embolism (PE) rose significantly for tumour, trauma and spinal patients.
  • CONCLUSION: The value of the database is demonstrated by its ability to provide analysis which shows statistically significant changes over time.
  • [MeSH-minor] Adult. Brain Diseases / drug therapy. Databases, Factual. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Health Facilities.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14642362.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


32. Sunitinib: new drug. For some gastrointestinal stromal tumours. Prescrire Int; 2007 Aug;16(90):138-41
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sunitinib: new drug. For some gastrointestinal stromal tumours.
  • (1) Sunitinib, a tyrosine kinase inhibitor, is marketed for the treatment of advanced-stage and metastatic renal carcinoma, and for second-line treatment of gastrointestinal stromal tumours.
  • Sorafenib arrived on the market almost simultaneously for second-line treatment of kidney cancer. (2) In second-line treatment of kidney cancer, two non comparative trials showed an unusually high rate of at least partial tumour regression with sunitinib (25%, compared to only 2% with sorafenib).
  • Head-to-head trials of the two drugs are lacking.
  • Although indirect comparisons are notoriously unreliable, sunitinib appears to provide longer progression-free survival than sorafenib (about 9 months versus 5.5 months), although overall survival times are similar. (3) Preliminary results of a trial comparing sunitinib with interferon alfa as first-line treatments in 750 patients with kidney cancer show a 6-month event-free survival advantage in the sunitinib arm.
  • The precise overall survival time has not yet been calculated. (4) In 312 patients with gastrointestinal stromal tumours in whom imatinib has failed, a double-blind placebo-controlled trial showed that sunitinib prolonged overall survival time, but potential biases undermine these results. (5) The adverse effect profile of sunitinib appears to be similar to those of imatinib and sorafenib, apart from more thyroid disorders.
  • Arterial hypertension, sometimes severe, occurred in 16% of patients treated with sunitinib.
  • Other serious adverse events included tumour haemorrhage and pulmonary embolism.
  • A risk of cardiac toxicity leading to heart failure cannot currently be ruled out. (6) Sunitinib is metabolised by cytochrome P450 isoenzyme CYP 3A4, increasing the likelihood of drug interactions. (7) These results support the use of sunitinib as second-line therapy for patients with gastrointestinal stromal tumours.
  • In first-line treatment of kidney cancer, it is preferable to wait for detailed results of the ongoing trial, especially effects on survival time, before judging the possible advantages and disadvantages of sunitinib compared to interferon alfa.
  • In second-line treatment, sorafenib is better-assessed than sunitinib and should therefore be preferred, pending a direct comparison of the two drugs.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents / therapeutic use. Gastrointestinal Stromal Tumors / drug therapy. Piperazines / therapeutic use. Pyrroles / therapeutic use
  • [MeSH-minor] Humans. Hypothyroidism / complications. Indoles / adverse effects. Indoles / therapeutic use. Interferon-alpha / adverse effects. Interferon-alpha / therapeutic use. Kidney Neoplasms / complications. Kidney Neoplasms / drug therapy. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / adverse effects. Pyrimidines / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17724833.001).
  • [ISSN] 1167-7422
  • [Journal-full-title] Prescrire international
  • [ISO-abbreviation] Prescrire Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Indoles; 0 / Interferon-alpha; 0 / Piperazines; 0 / Pyrimidines; 0 / Pyrroles; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


33. Castelli R, Porro F, Tarsia P: The heparins and cancer: review of clinical trials and biological properties. Vasc Med; 2004 May;9(3):205-13
Hazardous Substances Data Bank. HEPARIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The spectrum of thromboembolic manifestations in cancer patients includes deep vein thrombosis, pulmonary embolism, but also intravascular disseminated coagulation and abnormalities in the clotting system in the absence of clinical manifestations.
  • Unfractionated heparin (UFH) and particularly low molecular weight heparins (LMWH-s) are widely used for the prevention and treatment of thromboembolic manifestations that commonly accompany malignancies.
  • Heparins may play a role in tumour cell growth and in cancer dissemination.
  • The aims of the study are to review the efficiency of heparins in the prevention and treatment of cancer-related thromboembolic complications, and review the biological effects of heparins.
  • Meta-analyses comparing unfractionated heparins and LMWH-s for the treatment of deep vein thrombosis have shown better outcome with a reduction of major bleeding complications in patients treated with LMWH-s.
  • (2) tumour cell heparinases that mediate tumour cell invasion and metastasis;.
  • (3) cell surface selectin-mediated tumour cell metastasis and blood coagulation.
  • The above evidence, together with favourable pharmaco-properties and with a reduction in major bleeding complications, suggests an important role for LMWH-s in thromboprophylaxis and in the therapy of venous thromboembolism in cancer patients.
  • [MeSH-major] Fibrinolytic Agents / therapeutic use. Heparin / pharmacology. Heparin / therapeutic use. Neoplasms / complications
  • [MeSH-minor] Animals. Cell Proliferation / drug effects. Clinical Trials as Topic. Endothelial Cells / drug effects. Humans. Neovascularization, Pathologic / prevention & control. Pulmonary Embolism / etiology. Pulmonary Embolism / prevention & control. Thromboembolism / etiology. Thromboembolism / prevention & control. Vascular Endothelial Growth Factor A / drug effects. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15675186.001).
  • [ISSN] 1358-863X
  • [Journal-full-title] Vascular medicine (London, England)
  • [ISO-abbreviation] Vasc Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fibrinolytic Agents; 0 / Vascular Endothelial Growth Factor A; 9005-49-6 / Heparin
  • [Number-of-references] 85
  •  go-up   go-down


34. Tesselaar ME, Osanto S: Risk of venous thromboembolism in lung cancer. Curr Opin Pulm Med; 2007 Sep;13(5):362-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Other risk factors are pneumonectomy, metastatic disease, use of specific chemotherapeutic drugs in combination with novel targeted drugs, such as antiangiogenic agents, and elevated prechemotherapy platelet counts.
  • Tissue factor (TF), the initiator of the clotting cascade, may be (over)expressed in lung carcinoma cells.
  • Active TF-bearing microparticles, which may originate from the tumour cells themselves, have been found in the circulation of cancer patients.
  • SUMMARY: Risk factors of VTE in lung cancer patients are adenocarcinoma, metastatic disease, pneumonectomy and anticancer therapy including chemotherapy and anti-VEGF targeted drugs.
  • [MeSH-major] Lung Neoplasms / complications. Pulmonary Embolism / etiology. Venous Thrombosis / epidemiology


35. Grass H, Schuff A, Staak M, Dienes HR, von Both I: Tumor embolism as a cause of an unexpected death: a case report. Pathol Res Pract; 2003;199(5):349-52
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor embolism as a cause of an unexpected death: a case report.
  • Often, the symptoms implicate a variety of factors, and an autopsy is thus required to obtain the correct diagnosis.
  • This study analyzes the death of a 45-year-old woman who reportedly died from an acute pulmonary dysfunction.
  • Suspicious coin lesions detected by chest X-ray prompted a clinical clarification; however, no final diagnosis was made.
  • The autopsy revealed a bulky thyroid tumor with venous invasion, leading to a massive pulmonary tumor embolism.
  • Furthermore, microscopy identified the tumor as a rare pleomorphic myxoid sarcoma.
  • Thus, the patient died of a large pulmonary tumor embolism originating from this rare sarcoma, and not of acute pulmonary dysfunction of any other means.
  • [MeSH-major] Cause of Death. Neoplastic Cells, Circulating / pathology. Pulmonary Embolism / etiology. Sarcoma / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Female. Humans. Middle Aged. Pneumonia / complications. Pneumonia / drug therapy

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12908527.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


36. Kloos C, Müller UA, Höffken K, Schreiber J, Metzner U, Hertel K, Raabe G: [Paraneoplastic pityriasis rubra pilaris in metastatic adenocarcinoma without diagnosable primary]. Dtsch Med Wochenschr; 2002 Mar 1;127(9):437-40
Hazardous Substances Data Bank. ACITRETIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HISTORY AND ADMISSION FINDINGS: A 75-year-old woman, without a history of severe illness, developed an erythematosquamous skin disease on hands and forearms.
  • TREATMENT AND COURSE: The erythrodermia only temporarily receded under systemic therapy with acitretin and prednisolone.
  • The patient developed intermittent septic fever accompanied by reduction or loss of consciousness.
  • The patient died from paraneoplastic pulmonary embolism.
  • A necrosis in the right breast containing tumour cell remnants could probably be regarded as the primary neoplasm.
  • [MeSH-minor] Acitretin / administration & dosage. Acitretin / therapeutic use. Aged. Anti-Inflammatory Agents / administration & dosage. Anti-Inflammatory Agents / therapeutic use. Biopsy. Drug Therapy, Combination. Female. Humans. Immunohistochemistry. Keratolytic Agents / administration & dosage. Keratolytic Agents / therapeutic use. Prednisolone / administration & dosage. Prednisolone / therapeutic use. Skin / pathology

  • Genetic Alliance. consumer health - Pityriasis rubra pilaris.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11870558.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Keratolytic Agents; 9PHQ9Y1OLM / Prednisolone; LCH760E9T7 / Acitretin
  •  go-up   go-down






Advertisement